Nichtseminom im klinischen Stadium I

Rübben H (2008) Uroonkologie, Aufl. 4. Springer, Berlin Travis LB, Curtis RE, Storm H et al (1997) Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 89:1429–1439 Bokemeyer C, Schmoll HJ (1993) Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 11:1703–1709 Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ (1996) Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14:2923–2932 Kollmannsberger C, Beyer J, Droz JP et al (1998) Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 16:3386–3391 Belt-Dusebout AW van den, Wit R de, Gietema JA et al (2007) Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 25:4370–4378 Wood L, Kollmannsberger C, Jewett M et al (2010) Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 4:e19–e38 Leibovitch I, Foster RS, Kopecky KK et al (1998) Identification of clinical stage a nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol 16:261–268 Freedman LS, Parkinson MC, Jones WG et al (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 2:294–298 Albers P, Siener R, Kliesch S et al (2003) Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 21:1505–1512 Albers P, Bierhoff E, Neu D et al (1997) Mib-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer 79:1710–1716 Cullen MH, Stenning SP, Parkinson MC et al (1996) Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council Report. J Clin Oncol 14:1106–1113 Ulbright TM, Orazi A, Riese W de et al (1994) The correlation of P53 protein expression with proliferative activity and occult metastases in clinical stage I non-seminomatous germ cell tumors of the testis. Mod Pathol 7:64–68 Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW (1998) Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83:1002–1011 Krege S, Beyer J, Souchon R et al (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part I. Eur Urol 53:478–496 Winter C, Albers P (2010) Testicular germ cell tumors: pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 7:43–53 Read G, Stenning SP, Cullen MH et al (1992) Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 10:1762–1768 Duran I SJ, Jewett MA, Anson-Cartwright L et al (2007) Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I Non-Seminomatous Germ Cell Tumors (NSGCT). J Clin Oncol 25:5021 Sturgeon JF, Moore MJ, Kakiashvili DM et al (2010) Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital’s experience. Eur Urol 59:556–562 Kollmannsberger C, Moore C, Chi KN et al (2009) Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol Oliver RT, Raja MA, Ong J, Gallagher CJ (1992) Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage 1 malignant teratoma on overall relapse rate of stage 1 cancer patients. J Urol 148:1453–1455 (discussion 1455–1456) Studer UE, Fey MF, Calderoni A et al (1993) Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. Eur Urol 23:444–449 Bohlen D, Borner M, Sonntag RW et al (1999) Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors. J Urol 161:1148–1152 Chevreau C, Mazerolles C, Soulie M et al (2004) Long-term efficacy of two cycles of bep regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. Eur Urol 46:209–214 (discussion 214–205) Nuver J, Smit AJ, Wolffenbuttel BH et al (2005) The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 23:3718–3725 Travis LB, Fossa SD, Schonfeld SJ et al (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 97:1354–1365 Albers P, Siener R, Krege S et al (2008) Randomized phase iii trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: Auo Trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26:2966–2972 Westermann DH, Schefer H, Thalmann GN et al (2008) Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 179:163–166 Tandstad T, Dahl O, Cohn-Cedermark G et al (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the swenoteca management program. J Clin Oncol 27:2122–2128 Baniel J, Foster RS, Rowland RG et al (1994) Complications of primary retroperitoneal lymph node dissection. J Urol 152:424–427 Donohue JP, Thornhill JA, Foster RS et al (1993) Primary retroperitoneal lymph node dissection in clinical stage a non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. Br J Urol 71:326–335 Sharir S, Jewett MA, Sturgeon JF et al (1999) Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. J Urol 161:472–475 (discussion 475–476) Heidenreich A, Albers P, Hartmann M et al (2003) Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. J Urol 169:1710–1714 Nelson JB, Chen RN, Bishoff JT et al (1999) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 54:1064–1067 Nielsen ME, Lima G, Schaeffer EM et al (2007) Oncologic efficacy of laparoscopic RPLND in treatment of clinical stage I nonseminomatous germ cell testicular cancer. Urology 70:1168–1172 Rassweiler JJ, Frede T, Lenz E et al (2000) Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 37:251–260 Janetschek G, Hobisch A, Peschel R et al (2000) Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol 163:1793–1796 Williams SB, Lau CS, Josephson DY (2011) Initial series of robot-assisted laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer. Eur Urol 60:1299–1302 Cathomas R, Hartmann M, Krege S et al (2011) Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 34:59–64 Albers P, Albrecht W, Algaba F et al (2011) EAU guidelines on testicular cancer: 2011 update. Eur Urol 60:304–319 Rustin GJ, Mead GM, Stenning SP et al (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: medical research council trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25:1310–1315